Oncoteq AG

Oncoteq AG

Biotechnologieforschung

Zug, ZG 279 Follower:innen

Leveraging AI to unleash the full potential of molecules in oncology

Info

Oncoteq AG is a biotechnology company that in-licenses and develops drug molecules for oncology indications - enabled by artificial intelligence (AI) as part of Cureteq AG group First asset is an MetAP2 inhibitor, licensed from Merck KGaA, currently in phase 1 clinical development for oncology indications.

Website
www.cureteq.com
Branche
Biotechnologieforschung
Größe
2–10 Beschäftigte
Hauptsitz
Zug, ZG
Gegründet
2022
Spezialgebiete
Oncology, Drug Development, Artificial Intelligence, Biotechnology und Clinical Trials

Verbundene Seiten

Ähnliche Seiten